|
Session 13
Poster Discussion
Poster Discussion: Emerging Patterns of Resistance to New Antiretrovirals
Monday, 2-3 pm
Room: Room 302-304 |
| 869 |
An Enhanced Version of the Trofile HIV Co-receptor Tropism Assay Predicts Emergence of CXCR4 Use in ACTG5211 Vicriviroc Trial Samples
Jacqueline Reeves*1, D Han1, T Wilkin2, T Wrin1, D Kuritzkes3, C Petropoulos1, J Whitcomb1, N Parkin1, R Gulick2, and E Coakley1
1Monogram Biosci, South San Francisco, CA, US; 2Weill Med Coll of Cornell Univ, New York, NY, US; and 3Brigham and Women`s Hosp, Cambridge, MA, US |
| 870 |
Emergence in vivo of Vicriviroc Resistance in HIV-1 Subtype C: Role of V3 Loop and Susceptibility to Other CCR5 Antagonists
Athe M.N. Tsibris*1,2, M Sagar2,3, Z Su4, C Flexner5, W Greaves6, P Skolnik7, E Coakley8, M Subramanian9, R Gulick10, and D Kuritzkes2,3
1Massachusetts Gen Hosp, Boston, US; 2Harvard Med Sch, Boston, MA, US; 3Brigham and Women`s Hosp, Boston, MA, US; 4Harvard Sch of Publ Hlth, Boston, MA, US; 5Johns Hopkins Univ, Baltimore, MD, US; 6Schering-Plough Res Inst, Kenilworth, NJ, US; 7Boston Med Ctr, MA, US; 8Monogram Biosci, South San Francisco, CA, US; 9Human Genome Sci, Rockville, MD, US; and 10Weill Med Coll of Cornell Univ, New York, NY, US |
| 871 |
Changes in V3 Loop Sequence Associated with Failure of Maraviroc Treatment in Patients Enrolled in the MOTIVATE 1 and 2 Trials
Marilyn Lewis*1, J Mori1, P Simpson1, J Whitcomb2, X Li3, D Roberston1, and M Westby1
1Pfizer Global R&D, Sandwich Labs, Kent, UK; 2Monogram Biosci, South San Francisco, CA, US; and 3Faculty of Life Sci, Univ of Manchester, UK |
| 872 |
Naturally Occurring Polymorphisms in HIV-1 Group M, N, and O Integrase: Implications for Integrase Inhibitors
John Hackett Jr*, B Harris, V Holzmayer, J Yamaguchi, K C Luk, C Brennan, G Schochetman, S Devare, and P Swanson
Abbott Diagnostics, Abbott Park, IL, US |
| 873 |
Development of vircoTYPE HIV-1 Resistance Analysis, Including Clinical Cutoffs for TMC125, a New NNRTI
Bart Winters*1, J Vingerhoets2, M Peeters2, J Villacian1, E Van Craenenbroeck1, and L Bacheler3
1Virco BVBA, Mechelen, Belgium; 2Tibotec BVBA, Mechelen, Belgium; and 3VircoLab Inc, Durham, NC, US |
| 874 |
Characterization of Virologic Failures on Darunavir/Ritonavir in the Randomized, Controlled, Phase III TITAN Trial in Treatment-experienced Patients
Sandra De Meyer*1, E Lathouwers1, I Dierynck1, E De Paepe1, B Van Baelen1, T Vangeneugden1, S Spinosa-Guzman1, G Picchio2, and M P de Bethune1
1Tibotec BVBA, Mechelen, Belgium and 2Tibotec Inc, Yardley, PA, US |
|
